Table 1.

Potential Anti-Covid-19 Therapeutic Treatments.

PHASES AND SYMPTOMS	THERAPEUTIC TARGETS	THERAPEUTIC INTERVENTIONS
1) VIRAL PHASE      (about 1–5° days) Inflammation of first air ducts and eyes (rhinitis, pharyngitis, conjunctivitis). Inflammation of middle air tracts (tracheitis, bronchitis, fever, cough)	- Blocking inflammation factors     and histamine (amplifying inflammatory effects) - Neutralizing the virus for preventing its replication and a consequent Ag excess condition	- Anti-inflammation drugs         - Anti-histamine drugs - Anti-Spike (RBD, NTD) mFabs
2) IMMUNOLOGICAL PHASE (about 6–10° days) Inflammation of the lower air tracts and pulmonary alveoli, dyspnea, tissue and vascular C-mediated lesions	- Blocking the IC formation by neutralization of the viral Ags without involving the C system            - Blocking the complement cascade activation and its systemic effects	-Anti-spike(RBD) mFabs  or -Anti-spike(RBD) micro-Abs - C1 INH (inhibitor of C1), already in use as a drug for hereditary angioedema and other extravasation diseases
3) HEMO-VASCULAR PHASE (about 11–15° days and more)     Tissue and vascular lesions, thrombus formation, extravasation (interstitial pneumonia, renal, heart, brain, and skin damages)	- Preventing platelet aggregation and activation - Blocking the fibrin synthesis process    -Dissolving the systemic micro- vascular thrombi	- Acetyl salicylic acid    - Anti-histamine drugs - Anti-coagulant drugs    - Fibrin-lytic agents